Фибрилляция предсердий при тиреотоксикозе – детерминанты развития и сохранения
https://doi.org/10.14341/ket20139129-37
Аннотация
Об авторах
A Yu Babenkoканд. мед. наук, заведующая НИЛ сосудистых осложнений сахарного диабета института эндокринологии ФЦСКЭ им. В.А. Алмазова
E N Grineva
доктор мед. наук, директор института эндокринологии ФЦСКЭ им. В.А. Алмазова
V N Solncev
канд. мат. наук, старший научный сотрудник НИЛ математического моделирования ФЦСКЭ им. В.А. Алмазова
Список литературы
1. Бабенко А.Ю. Тиреотоксическая кардиомиопатия: факторы риска и предикторы развития. Обзоры по клинической фар макологии и лекарственной терапии. 2011; 9 (3): 49–59.
2. Бабенко А.Ю., Гринева Е.Н., Солнцев В.Н., Цой У.А., Шлях то Е.В. Вклад различных факторов в характер поражения сердца при тиреотоксикозе. Мед. акад. журн. 2012. 10 (1): 6–12.
3. Боровиков В. Statistical искусство анализа данных на компью тере. Для профессионалов. СПб.: Питер, 2001. 656 с.
4. Ланг Т., Сесик М. Как описывать статистику в медицине. Ан нотированное руководство для авторов, редакторов и рецен зентов. М.: Практическая медицина, 2011. 480 с.
5. Орлов В.Н. Руководство по электрокардиографии. 6е изд., стереот. М.: Мед. информ. агентство, 2007. 525 с.
6. Шустов С.Б., Кицышин В.П. Особенности суточного распре деления нарушений ритма у больных с эндокринными кар диомиопатиями. Рус. мед. журн. http://www.rusmg.ru/php/ contents.php?id=9275
7. Auer J., Scheibner P., Mische T. et al. Subclinical hyperthyroidism as a risk factor for atrial fibrillation. Am. Heart. J. 2001; 142: 838–842.
8. Bahn R.S. et al. Hyperthyroidism and other causes of thyrotoxico sis: management guidelines of the american thyroid association and american association of clinical endocrinologists. Endocrinol. Pract. 2011; 17: 456–520.
9. Cappola A.R., Fried L.P., Arnold A.M. et al. Thyroid status, cardio vascular risk, and mortality in older adults. JAMA 2006; 295 (9): 1033–1041.
10. Ching G.W., Franklyn J.A., Stallard T.J. et al. Cardiac hypertrophy as a result of longterm thyroxine therapy and thyrotoxicosis. Heart 1996; 75: 363–368.
11. De Simone G. Concentric or eccentric hypertrophy: how clinically relevant is the difference? Hypertension 2004; 43 (4): 714–715.
12. Donatelli M., Assennato P., Abbadi V. et al. Cardiac changes in sub clinical and overt hyperthyroid women: retrospective study. Int.
13. J. Cardiol. 2003; 90: 159–164.
14. Dorr M., Wolff B., Robinson D.M. et al. The association of thyroid function with cardiac mass and left ventricular hypertrophy. J. Clin. Endocrinol. Metab. 2005; 90 (2): 673–677.
15. Dougherty M., Craige E. Apathetic hyperthyroidism presenting as tricuspid regurgitation. Chest. 1973; 63: 767–772.
16. Dunn M., Alexander J., de Silva R., Hildner F. Antithrombotic ther apy in atrial fibrillation. Chest. 1989; 95 (Suppl. 2): 118S–127S.
17. Ganau A., Devereux R.B., Roman M.J. et al. Patterns of left ven tricular hypertrophy and geometric remodeling in essential hyper tension. J. Am. Coll. Cardiol. 1992; 19: 1550–1558.
18. Flynn R.W.V., McDonald T.M., Jung R.T. et al. Mortality and vas cular outcomes in patients treated for thyroid dysfunction. J. Clin. Endocrinol. Metab. 2006; 91 (6): 2159–2164.
19. Franklyn J.A., Sheppard M.C., Maisonneuve P. Thyroid function and mortality in patients treated for hyperthyroidism. JAMA 2005; 294 (1): 71–80.
20. Frost L., Vestergaard P., Mosekilde L. Hyperthyroidism and risk of atrial fibrillation or flutter: a populationbased study. Arch. Intern. Med. 2004; 164: 1675–1678.
21. Iwasaki T., Naka M., Hiramatsu K. Echocardiographic studies on the relationship between atrial fibrillation and atrial enlargement in patients with hyperthyroidism of Graves' disease. Cardiology 1989; 76 (1): 10–17.
22. Lang R.M., Biering M., Devereux R.B. et al. Recommendations for chamber quantification: a report from the American of Society Echocardiography's guidelines and standards committee and the chamber quantification writing group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J. Am. Soc. Echocardiogr. 2005; 18: 1440–1463.
23. Marcisz C., Jonderko G., Wroblewski T. et al. Left ventricular mass in patients with hyperthyroidism. Med. Sci Monit. 2006; 12 (11): 481–486.
24. Marti V., Ballester M., Rigla M. et al. Myocardial damage does not occur in untreated hyperthyroidism unless associated with conges tive heart failure. Am. Heart J. 1997. 134 (6): 1133–1137.
25. Marvisi M., Zambrelli P., Brianty M. et al. Pulmonary hypertension is frequent in hyperthyroidism and normalizes after therapy. Eur. J. Intern. Med. 2006; 17 (4): 267–271.
26. Merce J., Ferras S., Oltra C. et al. Cardiovascular abnormalities in hyperthyroidism: A prospective Doppler echocardiographic study. Am. J. Med. 2005; 118: 126–131.
27. Metso S., Auvinen A., Salmi J. еt al. Increased longterm cardiovas cular morbidity among patients treated with radioactive iodine for hyperthyroidism. Clin. Endocrinol. 2007; 92: 2190–2196.
28. Mintz G., Pizzarello R., Klein I. Enhanced left ventricular diastolic function in hyperthyroidism: noninvasive assessment and response to treatment. J. Clin. Endocrinol Metab. 1991; 73: 146–150.
29. Nakazawa H. et al. Is there a place for the late cardioversion of atri al fibrillation? A longterm followup study of patients with post thyrotoxic atrial fibrillation. Eur. Heart J. 2000; 21: 327–333.
30. Nakchbandi I.A., Wirth J.A., Inzucchi S.E. Pulmonary hyperten sion caused by Graves’ thyrotoxicosis normal pulmonary hemody namics restored by 131I treatment. Chest. 1999; 116: 1483–1485.
31. Osman F., Daykin J., Sheppard M. et al. Cardiac rhythm abnor malities in thyrotoxicosis — the explanation for excess vascular mortality. J. Endocrinol. 2000; 164: 321–322.
32. Petersen P., Hansen J.M. Stroke in thyrotoxicosis with atrial fibril lation. Stroke 1988; 19: 15–18.
33. Rubin L.J., Badesch D.B. Thyrotoxicosis as a risk factor for pul monary arterial hypertension. Ann. Intern. Med. 2006; 144 (3): 222–223.
34. Sandier G., Wilson G. The nature and prognosis of heart disease in thyrotoxicosis: a review of 150 patients treated with I131. QJM 1959; 28: 347–352.
35. Sheu J.J., Kang J.H., Lin H.C. et al. Hyperthyroidism and risk of ischemic stroke in young adults. Stroke 2010; 41 (5): 961–966.
36. Siu C.W., Yeung C.Y., Lau C.P. et al. Incidence, clinical character istics and outcome of congestive heart failure as the initial presen tation in patients with primary hyperthyroidism. Heart 2007; 93: 483–487.
37. Soh М.С., Croxson М. Fatal thyrotoxic cardiomyopathy in a young man. BMJ 2008; 337: 531.
38. Tenerz A., Forberg R., Jansson R. Is a more active attitude warrant ed in patients with subclinical thyrotoxicosis? J. Intern. Med. 1990; 228: 229–233.
39. Toft A., Boon N. Thyroid disease and the heart. Heart 2000; 84: 455–460.
Рецензия
Для цитирования:
Babenko A.Yu., Grineva E.N., Solncev V.N. Фибрилляция предсердий при тиреотоксикозе – детерминанты развития и сохранения. Клиническая и экспериментальная тиреоидология. 2013;9(1):29-37. https://doi.org/10.14341/ket20139129-37
For citation:
, , Determinants of development and preservation of atrial fibrillation at thyrotoxicosis. Clinical and experimental thyroidology. 2013;9(1):29-37. (In Russ.) https://doi.org/10.14341/ket20139129-37
Контент доступен под лицензией Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).